| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/01/2013 | WO2013110198A1 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
| 08/01/2013 | WO2013110152A1 Pharmaceutical compositions containing angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis activators for the treatment of ocular pathological conditions |
| 08/01/2013 | WO2013110135A1 Heterocyclic compounds and methods for their use |
| 08/01/2013 | WO2013110134A1 Heterocyclic compounds and methods for their use |
| 08/01/2013 | WO2013086444A3 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
| 08/01/2013 | WO2013086441A3 Oligonucleotide analogues targeting human lmna |
| 08/01/2013 | WO2013086266A3 Allosteric modulators of 5-hydroxytryptamine 2c receptor (5-ht2cr) |
| 08/01/2013 | WO2013083813A3 Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis |
| 08/01/2013 | WO2013083578A3 Microbicidal composition |
| 08/01/2013 | WO2013071456A3 Injectable veterinary composition for sustained release of ceftiofur and florfenicol in animal species, which comprises poly(lacticcoglycolic acid) (plga) microparticles, and the method for the preparation thereof |
| 08/01/2013 | WO2013056070A3 Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
| 08/01/2013 | WO2013055302A9 Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline |
| 08/01/2013 | WO2013054866A8 Agent for preventing or treating htlv-i associated myelopathy |
| 08/01/2013 | WO2013054178A3 Extended release pharmaceutical compositions containing carmabazepine |
| 08/01/2013 | WO2013041967A3 Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| 08/01/2013 | WO2013033407A9 Identification of small molecules that enhance therapeutic exon skipping |
| 08/01/2013 | WO2013029057A4 Compositions and methods for treating neurodegenerative disease |
| 08/01/2013 | WO2013019731A3 Phosphate prodrugs |
| 08/01/2013 | WO2012120099A3 Small molecule modulators of the cold and menthol receptor trpm8 |
| 08/01/2013 | WO2012111016A8 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof |
| 08/01/2013 | WO2012068274A9 Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
| 08/01/2013 | WO2012061248A8 Novel specific hcv ns3 protease inhibitors |
| 08/01/2013 | WO2012006474A3 Compounds and methods for inhibiting phosphate transport |
| 08/01/2013 | WO2012006419A3 Pro-neurogenic compounds |
| 08/01/2013 | WO2009036412A8 Modulators of cystic fibrosis transmembrane conductance regulator |
| 08/01/2013 | US20130198875 Rna sequence-specific mediators of rna interference |
| 08/01/2013 | US20130197444 Regimens for intra-articular viscosupplementation |
| 08/01/2013 | US20130197212 Hydroxyalkyl starch for the treatment of head and neck cancers by reduction of tumor growth rates |
| 08/01/2013 | US20130197211 Hydroxyalkyl starch for the treatment of cancers by reduction of tumor growth rates |
| 08/01/2013 | US20130197103 Composition and method for the enhancement of the efficacy of drugs |
| 08/01/2013 | US20130197097 Novel spiroenone and uses thereof |
| 08/01/2013 | US20130197095 Substituted 4-aminocyclohexane derivatives |
| 08/01/2013 | US20130197094 Trpv1 compounds in a biodegradable polymer carrier |
| 08/01/2013 | US20130197093 Enhanced bimatoprost ophthalmic solution |
| 08/01/2013 | US20130197092 Novel Non-Aqueous Topical Solution of Diclofenac and Process for Preparing the Same |
| 08/01/2013 | US20130197091 Use of adrenergic beta-e-receptor blockers in cancer treatment |
| 08/01/2013 | US20130197090 Postural stability and incident functions in patients |
| 08/01/2013 | US20130197089 Compositions for the treatment of actinic keratosis |
| 08/01/2013 | US20130197088 Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO) |
| 08/01/2013 | US20130197087 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy |
| 08/01/2013 | US20130197086 Procedure for the obtainment of fatty acids of pharmacological and nutritional interest |
| 08/01/2013 | US20130197085 Agent and method for stabilizing membrane protein |
| 08/01/2013 | US20130197084 Nutrient sensor |
| 08/01/2013 | US20130197081 Intravaginal administration of misoprostol |
| 08/01/2013 | US20130197080 Use of teriflunomide for treating multiple sclerosis |
| 08/01/2013 | US20130197076 Treatment of circadian rhythm disorders |
| 08/01/2013 | US20130197075 Method of treating acquired perforating dermatosis with cantharidin |
| 08/01/2013 | US20130197074 Use of adrenergic beta-3-receptor agonists in anti-aging |
| 08/01/2013 | US20130197069 Methods for treating stress induced emotional disorders |
| 08/01/2013 | US20130197066 Compositions and methods for treating viral infections |
| 08/01/2013 | US20130197058 Inhibiting striated muscle activator of rho (stars) to improve glycemic control |
| 08/01/2013 | US20130197057 Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas |
| 08/01/2013 | US20130197056 Novel biomarkers and targets for ovarian carcinoma |
| 08/01/2013 | US20130197051 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 08/01/2013 | US20130197050 Novel lactams and uses thereof |
| 08/01/2013 | US20130197049 Compounds for treatment of cancer |
| 08/01/2013 | US20130197047 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 08/01/2013 | US20130197046 Novel p2x7r antagonists and their use |
| 08/01/2013 | US20130197044 Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists |
| 08/01/2013 | US20130197041 Gabr-a2 diagnostic |
| 08/01/2013 | US20130197038 Compositions And Methods For Neovascularization |
| 08/01/2013 | US20130197036 Transdermal absorption preparation |
| 08/01/2013 | US20130197035 Surgical Adjuvant Composition and Associated Methods of Use |
| 08/01/2013 | US20130197034 Salts Of Methyl 2-((R)-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3-((R)-Tetrahydro-2H-Pyran-3-Yl)Propylcarbamoyl)Piperidin-3-Yl)Methoxy)Ethylcarbamate |
| 08/01/2013 | US20130197032 Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders |
| 08/01/2013 | US20130197028 nAChRalpha7 Agonists and nAChRalpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD) |
| 08/01/2013 | US20130197025 A3 adenosine receptor allosteric modulators |
| 08/01/2013 | US20130197023 Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors |
| 08/01/2013 | US20130197022 3-cyano-quinoline derivatives with antiproliferative activity |
| 08/01/2013 | US20130197021 Combination of active loaded granules with additional actives |
| 08/01/2013 | US20130197020 Method of Providing Sustained Analgesia With Buprenorphine |
| 08/01/2013 | US20130197019 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| 08/01/2013 | US20130197017 Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-11g |
| 08/01/2013 | US20130197016 Dosing regimes for the treatment of ocular vascular disease |
| 08/01/2013 | US20130197015 Novel method to improve the safety and efficacy of caffeine |
| 08/01/2013 | US20130197014 Purinone compounds as kinase inhibitors |
| 08/01/2013 | US20130197012 Compounds for the Treatment of Hepatitis C |
| 08/01/2013 | US20130197010 Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| 08/01/2013 | US20130197005 Parenteral Formulations Of Dopamine Agonists |
| 08/01/2013 | US20130197003 Methods and compositions for treating or preventing erythema |
| 08/01/2013 | US20130197002 Brimonidine for treating visual disorders mediated by central visual projections from the eye |
| 08/01/2013 | US20130197001 Substituted heterocyclic compounds |
| 08/01/2013 | US20130197000 Drug and food/drink for preventing or improving cerebral dysfunction |
| 08/01/2013 | US20130196997 Dual-acting oxazole antihypertensive agents |
| 08/01/2013 | US20130196996 Use of isoxazoline compounds and compositions in bladder cancer |
| 08/01/2013 | US20130196995 Combination of brimonidine and timolol for topical ophthalmic use |
| 08/01/2013 | US20130196994 Pde10 inhibitors and related compositions and methods |
| 08/01/2013 | US20130196992 1',3'-disubstituted-4-pheny-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| 08/01/2013 | US20130196989 Compositions and methods for inducing cell dedifferentiation |
| 08/01/2013 | US20130196987 Macrocyclic compounds useful as pharmaceuticals |
| 08/01/2013 | US20130196986 Triazolopyrazinones as p2x7 receptor antagonists |
| 08/01/2013 | US20130196983 Modulators of cystic fibrosis transmembrane conductance regulator |
| 08/01/2013 | US20130196977 Use of organic compounds |
| 08/01/2013 | US20130196976 Compositions for reducing beta-amyloid-induced neurotoxicity comprising beta-secretase inhibitor |
| 08/01/2013 | US20130196970 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| 08/01/2013 | US20130196969 Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
| 08/01/2013 | US20130196968 Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
| 08/01/2013 | US20130196966 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| 08/01/2013 | US20130196964 Heterocyclically substituted aryl compounds as hif inhibitors |
| 08/01/2013 | US20130196962 Non-hormonal steroid modulators of nf-kb for treatment of disease |